annb0t
Top 20
Telix Pharmaceuticals Limited
MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024).
Q2 2024 Financial Performance and Guidance Upgrade
The Company reports unaudited total revenue of approximately US$124M1 (AU$189M) primarily generated from sales of Telixâs prostate cancer imaging product Illuccix®. This represe...
>>> Read more: Q2 2024 Revenue and Business Highlights, Guidance Upgrade
MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024).
Q2 2024 Financial Performance and Guidance Upgrade
The Company reports unaudited total revenue of approximately US$124M1 (AU$189M) primarily generated from sales of Telixâs prostate cancer imaging product Illuccix®. This represe...
>>> Read more: Q2 2024 Revenue and Business Highlights, Guidance Upgrade